Voyageur Pharmaceuticals Ltd. VYYRF
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.90K | 14.00K | 500.00 | 8.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.90K | 14.00K | 500.00 | 8.00K | -- |
| Cost of Revenue | 11.90K | 14.00K | -1.60K | 10.10K | -- |
| Gross Profit | 0.00 | 0.00 | 2.00K | -2.10K | -- |
| SG&A Expenses | 629.40K | 426.30K | 564.30K | 772.30K | 266.50K |
| Depreciation & Amortization | 200.00 | 200.00 | 200.00 | 200.00 | 200.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 641.40K | 440.50K | 562.90K | 782.60K | 266.70K |
| Operating Income | -629.60K | -426.50K | -562.50K | -774.60K | -266.70K |
| Income Before Tax | -725.70K | -456.60K | -620.30K | -951.20K | -387.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -725.70K | -456.60K | -620.30K | -951.20K | -387.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -725.70K | -456.60K | -620.30K | -951.20K | -387.10K |
| EBIT | -629.60K | -426.50K | -562.50K | -774.60K | -266.70K |
| EBITDA | -629.40K | -426.30K | -562.30K | -774.40K | -266.50K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 179.02M | 178.59M | 178.37M | 167.45M | 161.17M |
| Average Diluted Shares Outstanding | 179.02M | 178.59M | 178.37M | 167.45M | 161.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |